ANGPTL3 and familial hypercholesterolemia: Preliminary results for a phase 1 study in healthy adult volunteers or patients with dyslipidemia, including familial hypercholesterolemia and severe hypertriglyceridemia, indicate potent and prolonged inhibition of ANGPTL3 levels (up to 93%) after two doses of ARO-ANG3 [37, 38].